Mandana Mahmoudi
Pulmonary Disease · New York, NYNPI 1942527148
Payments from drug & device makers
Across 54 payments — averaging $41.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$855
- Harmony Biosciences LLC$466
- Inspire Medical Systems, Inc.$216
- Axsome Therapeutics, Inc.$212
- ZOLL Respicardia, Inc.$148
- Lilly USA, LLC$112
- plus $223 from 6 others
What the payments were for
- Food & beverage$2,04291%
- Education$1909%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 12 | $855 |
| Harmony Biosciences LLC | 23 | $466 |
| Inspire Medical Systems, Inc. | 1 | $216 |
| Axsome Therapeutics, Inc. | 4 | $212 |
| ZOLL Respicardia, Inc. | 2 | $148 |
| Lilly USA, LLC | 4 | $112 |
| Itamar Medical Inc | 2 | $63 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $54 |
| UCB, Inc. | 1 | $39 |
| Advanced Respiratory, Inc | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XYWAV$354
- SUNOSI$255
- Inspire Upper Airway Stimulation System$216
- remede System$121
How this compares
$2,232 in reported general payments places this provider in the 55th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 27 | $273 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in New York
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Doreen Addrizzo-HarrisNew York$1.9M
- Emily DimangoNew York$1.4M
- da ZhangNew York$1.3M
- Claire KeatingNew York$1.2M
- Charles PowellNew York$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.